62075-55-2

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2,2-Dimethyl-1,3-dioxolane-4-carboxylic acid is used as a chemical intermediate for the synthesis of various pharmaceutical compounds due to its potential biological activities. Its unique structure allows it to be a versatile building block in the development of new drugs.
Used in Organic Synthesis:
In the field of organic synthesis, 2,2-Dimethyl-1,3-dioxolane-4-carboxylic acid is used as a key building block for the preparation of more complex molecules. Its dioxolane ring and carboxylic acid functionality make it a valuable component in the synthesis of various organic compounds.
Used in Antimicrobial and Antifungal Applications:
2,2-Dimethyl-1,3-dioxolane-4-carboxylic acid is used as an antimicrobial and antifungal agent due to its potential to inhibit the growth of various microorganisms. Its biological properties make it a promising candidate for the development of new antimicrobial and antifungal drugs.
Used in Disease Treatment Research:
2,2-Dimethyl-1,3-dioxolane-4-carboxylic acid is being investigated for its potential use in the treatment of various diseases. Its biological activities and unique chemical structure make it a valuable compound for exploring new therapeutic approaches in medicine.

InChI:InChI=1/C6H10O4/c1-6(2)9-3-4(10-6)5(7)8/h4H,3H2,1-2H3,(H,7,8)

Upstream product

• 100-79-8 (R,S)-2,2-dimethyl-1,3-dioxolane-4-methanol 
• 15186-48-8 2,3-isopropylidene-glyceraldehyde 
• 1707-77-3 1,2:5,6-di-O-isopropylidene-D-mannitol 
• 52373-72-5 methyl (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 55032-17-2 (4R)-4-benzyloxycarbonyl-2,2-dimethyl-1,3-dioxolane 
• 108865-84-5 methyl 2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 7306-64-1 2,3,5,6-di-O-isopropylidene-D-mannono-1,4-lactone 
• 60456-21-5 methyl (4S)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 117205-81-9 potassium (4S)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 5736-03-8 (d,l) isopropylidene glyceraldehyde 
• 134036-81-0 (4S,5S)-5-[(R)-((R)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-hydroxy-methyl]-2,2-dimethyl-[1,3]dioxolane-4-carboxylic acid anion 
• 22323-82-6 (S)-(+)-(2,2-dimethyl-[1,3]dioxolan-4-yl)methanol 
• 14028-61-6 potassium (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 22323-80-4 (4S)-2,2-dimethyl-[1,3]dioxolane-4-carbaldehyde 

Downstream Products

• 148065-34-3 (R)-2,2-dimethyl-1,3-dioxolane-4-carboxamide 
• 52373-72-5 methyl (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 
• 90493-96-2 2,2-dimethyl-1,3-dioxolane-4-carboxylic acid chloride 
• 99566-52-6 (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanone 
• 60456-21-5 methyl (4S)-2,2-dimethyl-1,3-dioxolane-4-carboxylate 

Relevant academic research and scientific papers

ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS

A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

THERAPEUTIC METHODS

The invention provides methods and compositions for delivering a nucleic acid to a cell or the cytosol of the target cell. The method includes contacting the cell with, 1) a membrane-destabilizing polymer; and 2) a nucleic acid conjugate. The nucleic acid conjugate includes a targeting ligand bound to an optional linker and a nucleic acid.

H-Phosphonate Synthesis and Biological Evaluation of an Immunomodulatory Phosphoglycolipid from Thermophilic Bacteria

The synthesis of a library of bacterial phosphoglycolipid, PGL-1, is described. Key features of the synthesis include regioselective esterification of the primary alcohol of the diacylglycerol moiety and an H-phosphonate method to install the phosphate in PGL-1 in comparison with earlier reported procedures. A representative set of PGL-1 analogues was prepared and evaluated for their biological activities. Results showed that the immunological activity of PGL-1 is dependent on the chain lengths of the fatty acids.

METHODS FOR TREATING HEPATITIS B INFECTIONS

Certain embodiments of the invention provide a method for identifying a patient that has a higher likelihood of responding to an HBV antigen inhibitor, such a method comprising detecting a hepatitis B virus (HBV) infected patient's genotype at one or more of the IL28B/A associated SNPs described herein, wherein the relevant genotype(s) described herein are indicative of a patient that has a higher likelihood of responding to an HBV antigen inhibitor as compared to an HBV infected patient having different genotypes at these locations.

TARGETED COMPOSITIONS

The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

Electrochemical Oxidation of Alcohols and Aldehydes to Carboxylic Acids Catalyzed by 4-Acetamido-TEMPO: An Alternative to "anelli" and "pinnick" Oxidations

An electrocatalytic method has been developed to oxidize primary alcohols and aldehydes to the corresponding carboxylic acids using 4-acetamido-2,2,6,6-tetramethylpiperidin-1-oxyl (ACT) as a mediator. The method successfully converts benzylic, aliphatic, heterocyclic, and other heteroatom-containing substrates to the corresponding carboxylic acids in aqueous solution at room temperature. The mild conditions enable retention of stereochemistry adjacent to the site of oxidation, as demonstrated in a 40 g-scale synthesis of a precursor to levetiracetam, a medication used to treat epilepsy.

[4-(1, 3, 3-TRIMETHYL-2-OXO-3, 4-DIHYDRO-1H-QUINOXALIN-7-YL) PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF

The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is u

TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS

The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

Synthesis of phospholipids on a glyceric acid scaffold: Design and preparation of phospholipase A2 specific substrates

Synthesis of a new series of phospholipid analogues to serve as activity-based probes of secretory phospholipase A2 enzymes is reported. The synthesis is based upon (1) preparation of long-chain esters and amides of glyceric acid, followed by (